Cara Therapeutics Q3 EPS $(0.74) Misses $(0.58) Estimate, Sales $5.8M Beat $4.34M Estimate

Cara Therapeutics (NASDAQ:CARA) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.58) by 27.59 percent. This is a 45.1 percent decrease over losses of $(0.51) per share

Benzinga · 11/05/2019 21:35

Cara Therapeutics (NASDAQ:CARA) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.58) by 27.59 percent. This is a 45.1 percent decrease over losses of $(0.51) per share from the same period last year. The company reported quarterly sales of $5.8 million which beat the analyst consensus estimate of $4.34 million by 33.64 percent. This is a 14.58 percent increase over sales of $5.062 million the same period last year.